TY - JOUR PY - 2013 DA - 2013// TI - Suicide Among Adults Aged 35–64 Years — United States, 1999–2010 JO - MMWR Morb Mortal Wkly Rep VL - 62 ID - ref1 ER - TY - JOUR AU - Olfson, M. PY - 2005 DA - 2005// TI - Emergency treatment of young people following deliberate self-harm JO - Arch Gen Psychiatry VL - 62 UR - https://doi.org/10.1001/archpsyc.62.10.1122 DO - 10.1001/archpsyc.62.10.1122 ID - Olfson2005 ER - TY - JOUR AU - Larkin, G. L. AU - Beautrais, A. L. PY - 2011 DA - 2011// TI - A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department JO - Int J Neuropsychopharmacol VL - 14 UR - https://doi.org/10.1017/S1461145711000629 DO - 10.1017/S1461145711000629 ID - Larkin2011 ER - TY - JOUR AU - Cipriani, A. PY - 2013 DA - 2013// TI - Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis JO - BMJ VL - 346 UR - https://doi.org/10.1136/bmj.f3646 DO - 10.1136/bmj.f3646 ID - Cipriani2013 ER - TY - JOUR AU - George, M. S. PY - 2014 DA - 2014// TI - A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients JO - Brain Stimul VL - 7 UR - https://doi.org/10.1016/j.brs.2014.03.006 DO - 10.1016/j.brs.2014.03.006 ID - George2014 ER - TY - JOUR AU - Fink, M. AU - Kellner, C. H. AU - McCall, W. V. PY - 2014 DA - 2014// TI - The role of ECT in suicide prevention JO - J ECT VL - 30 UR - https://doi.org/10.1097/YCT.0b013e3182a6ad0d DO - 10.1097/YCT.0b013e3182a6ad0d ID - Fink2014 ER - TY - JOUR AU - Striebel, J. M. AU - Kalapatapu, R. K. PY - 2014 DA - 2014// TI - The anti-suicidal potential of buprenorphine: a case report JO - Int J Psychiatry Med VL - 47 UR - https://doi.org/10.2190/PM.47.2.g DO - 10.2190/PM.47.2.g ID - Striebel2014 ER - TY - JOUR AU - Yovell, Y. PY - 2016 DA - 2016// TI - Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial JO - Am J Psychiatry VL - 173 UR - https://doi.org/10.1176/appi.ajp.2015.15040535 DO - 10.1176/appi.ajp.2015.15040535 ID - Yovell2016 ER - TY - JOUR AU - Greenwald, M. PY - 2007 DA - 2007// TI - Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices JO - Biol Psychiatry VL - 61 UR - https://doi.org/10.1016/j.biopsych.2006.04.043 DO - 10.1016/j.biopsych.2006.04.043 ID - Greenwald2007 ER - TY - JOUR PY - 2002 DA - 2002// TI - Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule JO - Fed Regist VL - 67 ID - ref10 ER - TY - JOUR AU - Ahmadi, J. PY - 2016 DA - 2016// TI - The effect of buprenorphine on the reduction of cannabis and heroin craving and suicidal thoughts: a new finding JO - iMedPub VL - 1 ID - Ahmadi2016 ER - TY - STD TI - Ahmadi J. Fast treatment of methamphetamine related anxiety and depressive disorders: a novel approach. J Addict Med Ther Sci. 1(2):044–6. https://doi.org/10.17352/2455-3484.000011. ID - ref12 ER - TY - JOUR AU - Ahmadi, J. PY - 2016 DA - 2016// TI - Instant detoxification of heroin with high dose of buprenorphine JO - J Addict Prev VL - 4 ID - Ahmadi2016 ER - TY - STD TI - Gracer R. The buprenorphine effect on depression. The National Alliance of Advocates for Buprenorphine Treatment (NAABT) Vol 3, No 2, Feb. 2007 newsletter. ID - ref14 ER - TY - BOOK PY - 2015 DA - 2015// TI - Kaplan & Sadock’s Synopsis of Psychiatry PB - Wilkins CY - Philadelphia ID - ref15 ER - TY - STD TI - Ahmadi J, Sefidfard Jahromi M. Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial. Subst Use Misuse. 2017;17:1–4. ID - ref16 ER - TY - JOUR AU - Ipser, J. C. AU - Terburg, D. AU - Syal, S. AU - Phillips, N. AU - Solms, M. AU - Panksepp, J. AU - van Honk, J. PY - 2013 DA - 2013// TI - Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers JO - Psychoneuroendocrinology VL - 38 UR - https://doi.org/10.1016/j.psyneuen.2012.05.002 DO - 10.1016/j.psyneuen.2012.05.002 ID - Ipser2013 ER - TY - JOUR AU - Maremmani, A. G. I. AU - Rovai, L. AU - Pani, P. P. AU - Pacini, M. AU - Lamanna, F. AU - Rugani, F. AU - Maremmani, I. PY - 2011 DA - 2011// TI - Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? JO - Ann General Psychiatry VL - 10 UR - https://doi.org/10.1186/1744-859X-10-17 DO - 10.1186/1744-859X-10-17 ID - Maremmani2011 ER - TY - JOUR AU - Falcon, E. AU - Maier, K. AU - Robinson, S. A. AU - Hill-Smith, T. E. AU - Lucki, I. PY - 2015 DA - 2015// TI - Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice JO - Psychopharmacology VL - 232 UR - https://doi.org/10.1007/s00213-014-3723-y DO - 10.1007/s00213-014-3723-y ID - Falcon2015 ER - TY - JOUR AU - Beck, A. T. AU - Steer RA AU - Ranieri WF PY - 1988 DA - 1988// TI - Scale for suicide ideation: psychometric properties of a self-report version JO - J Clin Psychol VL - 44 UR - https://doi.org/3.0.CO;2-6 DO - 3.0.CO;2-6 ID - Beck1988 ER - TY - JOUR AU - Soyka, M. PY - 2015 DA - 2015// TI - New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone JO - Subst Abuse Rehabil VL - 6 UR - https://doi.org/10.2147/SAR.S45585 DO - 10.2147/SAR.S45585 ID - Soyka2015 ER - TY - JOUR AU - Mintzer, M. Z. PY - 2007 DA - 2007// TI - Effects of opioid pharmacotherapy on psychomotor and cognitive performance: a review of human laboratory studies of methadone and buprenorphine JO - Heroin Addict Relat Clin Prob VL - 9 ID - Mintzer2007 ER - TY - JOUR AU - Darke, S. AU - Ross, J. PY - 1997 DA - 1997// TI - Polydrug dependence and psychiatric comorbidity among heroin injectors JO - Drug Alcohol Depend VL - 48 UR - https://doi.org/10.1016/S0376-8716(97)00117-8 DO - 10.1016/S0376-8716(97)00117-8 ID - Darke1997 ER - TY - JOUR AU - Ross, J. AU - Teesson, M. AU - Darke, S. PY - 2005 DA - 2005// TI - The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS) JO - Drug Alcohol Rev VL - 24 UR - https://doi.org/10.1080/09595230500286039 DO - 10.1080/09595230500286039 ID - Ross2005 ER - TY - JOUR AU - Rounsaville, B. J. AU - Weissman, M. M. AU - Crits-Christoph, K. AU - Wilber, C. AU - Kleber, H. PY - 1982 DA - 1982// TI - Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome JO - Arch Gen Psychiatry VL - 39 UR - https://doi.org/10.1001/archpsyc.1982.04290020021004 DO - 10.1001/archpsyc.1982.04290020021004 ID - Rounsaville1982 ER - TY - JOUR AU - Savant, J. D. AU - Barry, D. T. AU - Cutter, C. J. PY - 2013 DA - 2013// TI - Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment JO - Drug Alcohol Depend VL - 127 UR - https://doi.org/10.1016/j.drugalcdep.2012.06.020 DO - 10.1016/j.drugalcdep.2012.06.020 ID - Savant2013 ER - TY - JOUR AU - Schäfer, I. AU - Fischer, M. AU - Reimer, J. AU - Karow, A. AU - Haasen, C. PY - 2011 DA - 2011// TI - Significance of psychiatric comorbidity for the outcome of maintenance treatment — a review of the literature JO - Ment Health Subst Use VL - 4 UR - https://doi.org/10.1080/17523281.2011.533452 DO - 10.1080/17523281.2011.533452 ID - Schäfer2011 ER - TY - JOUR AU - Strain, E. C. PY - 2002 DA - 2002// TI - Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients JO - Clin J Pain VL - 18 UR - https://doi.org/10.1097/00002508-200207001-00003 DO - 10.1097/00002508-200207001-00003 ID - Strain2002 ER - TY - JOUR AU - Merikangas, K. R. AU - Mehta, R. L. AU - Molnar, B. E. PY - 1998 DA - 1998// TI - Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology JO - Addict Behav VL - 23 UR - https://doi.org/10.1016/S0306-4603(98)00076-8 DO - 10.1016/S0306-4603(98)00076-8 ID - Merikangas1998 ER - TY - JOUR AU - Merikangas, K. R. AU - Zhang, H. AU - Avenevoli, S. AU - Acharyya, S. AU - Neuenschwander, M. AU - Angst, J. PY - 2003 DA - 2003// TI - Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study JO - Arch Gen Psychiatry VL - 60 ID - Merikangas2003 ER - TY - JOUR AU - Moggi, F. PY - 2013 DA - 2013// TI - Etiological models on the relationship of mental disorders and substance use disorders JO - Suchtmed VL - 15 ID - Moggi2013 ER - TY - STD TI - Soyka M. Affective and anxiety disorders and drug addiction. Suchtmed, German. 2013;15:341–8. ID - ref32 ER - TY - JOUR AU - Darke, S. AU - Mills, K. AU - Teesson, M. AU - Ross, J. AU - Williamson, A. AU - Havard, A. PY - 2009 DA - 2009// TI - Patterns of major depression and drug-related problems amongst heroin users across 36 months JO - Psychiatry Res VL - 166 UR - https://doi.org/10.1016/j.psychres.2007.12.007 DO - 10.1016/j.psychres.2007.12.007 ID - Darke2009 ER - TY - JOUR AU - Torrens, M. AU - Martínez-Sanvisens, D. AU - Martínez-Riera, R. AU - Bulbena, A. AU - Szerman, N. AU - Ruiz, P. PY - 2011 DA - 2011// TI - Dual diagnosis: focusing on depression and recommendations for treatment of opioid dependence JO - Addict Disord Treat VL - 10 UR - https://doi.org/10.1097/ADT.0b013e318215f322 DO - 10.1097/ADT.0b013e318215f322 ID - Torrens2011 ER - TY - JOUR AU - Rothman, R. B. AU - Gorelick, D. A. AU - Heishman, S. J. PY - 2000 DA - 2000// TI - An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence JO - J Subst Abus Treat VL - 18 UR - https://doi.org/10.1016/S0740-5472(99)00074-4 DO - 10.1016/S0740-5472(99)00074-4 ID - Rothman2000 ER - TY - JOUR AU - Bodkin, J. A. AU - Zornberg, G. L. AU - Lukas, S. E. AU - Cole, J. O. PY - 1995 DA - 1995// TI - Buprenorphine treatment of refractory depression JO - J Clin Psychopharmacol VL - 15 UR - https://doi.org/10.1097/00004714-199502000-00008 DO - 10.1097/00004714-199502000-00008 ID - Bodkin1995 ER - TY - JOUR AU - Emrich, H. M. AU - Vogt, P. AU - Herz, A. AU - Kissling, W. PY - 1982 DA - 1982// TI - Antidepressant effects of buprenorphine JO - Lancet VL - 2 UR - https://doi.org/10.1016/S0140-6736(82)90727-9 DO - 10.1016/S0140-6736(82)90727-9 ID - Emrich1982 ER - TY - JOUR AU - Gerra, G. AU - Leonardi, C. AU - D’Amore, A. PY - 2006 DA - 2006// TI - Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study JO - Prog Neuro-Psychopharmacol Biol Psychiatry VL - 30 UR - https://doi.org/10.1016/j.pnpbp.2005.10.007 DO - 10.1016/j.pnpbp.2005.10.007 ID - Gerra2006 ER - TY - JOUR AU - Schmauss, C. AU - Yassouridis, A. AU - Emrich, H. M. PY - 1987 DA - 1987// TI - Antipsychotic effect of buprenorphine in schizophrenia JO - Am J Psychiatry VL - 144 UR - https://doi.org/10.1176/ajp.144.10.1340 DO - 10.1176/ajp.144.10.1340 ID - Schmauss1987 ER - TY - JOUR AU - Wee, S. AU - Koob, G. F. PY - 2010 DA - 2010// TI - The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse JO - Psychopharmacology VL - 210 UR - https://doi.org/10.1007/s00213-010-1825-8 DO - 10.1007/s00213-010-1825-8 ID - Wee2010 ER - TY - JOUR AU - Todtenkopf, M. S. AU - Marcus, J. F. AU - Portoghese, P. S. AU - Carlezon, W. A. PY - 2004 DA - 2004// TI - Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats JO - Psychopharmacology VL - 172 UR - https://doi.org/10.1007/s00213-003-1680-y DO - 10.1007/s00213-003-1680-y ID - Todtenkopf2004 ER -